A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu-pGSN) Following Intravenous Administration to Healthy Volunteers

Yao Liu[1], Susan L Levinson[1], Edward Kowalik[1], Jeremy Pronchik[1], Lester Kobzik[1], Mark J DiNubile[1]

Author affiliations

[1]BioAegis Therapeutics, North Brunswick, New Jersey, United States

Corresponding authors:

Dr. Susan Levinson, BioAegis Therapeutics, 685 US Highway One, North Brunswick, New Jersey, United States, email: slevinson@bioaegistx.com.

Dr. Yao Liu, BioAegis Therapeutics, 685 US Highway One, North Brunswick, New Jersey, United States, email: yliu@bioaegistx.com.

Key words: recombinant human plasma gelsolin (rhu-pGSN); acute lung injury; immunomodulation; anti-inflammatory

ABSTRACT

Background Plasma gelsolin (pGSN) is a non-immunosuppressive anti-inflammatory immunomodulator with demonstrated efficacy in animal models of acute lung injury. Its potential role in moderate-to-severe acute respiratory distress syndrome (ARDS) is currently under investigation.

Methods We conducted a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of recombinant human pGSN (rhu-pGSN) following intravenous (IV) administration to healthy volunteers. Thirty-two participants were assigned to 4 sequentially ascending dose cohorts (6, 12, 18, 24 mg/kg of body weight) to receive five IV infusions of rhu-pGSN or saline placebo. Each cohort includes 8 subjects randomized 3:1 with rhu-pGSN or placebo. Doses were administered at 0 hours, 12 hours, 36 hours, 60 hours, and 84 hours. The primary outcome is the incidence and severity of clinical and laboratory AEs regardless of causality. Secondary outcomes include the pharmacokinetics of IV rhu-pGSN and the presence of anti-rhu-pGSN antibodies at Day 28.

Results Overall, 10 subjects (41.7%) who received rhu-pGSN reported a total of 13 adverse events (AEs), and 1 subject (12.5%) who received placebo reported an AE. All AEs were mild or

38 moderate. AEs in system organ classes that were reported by 2 or more subjects in either arm
39 were skin and subcutaneous tissue disorders (12.5% rhu-pGSN; 0% placebo), gastrointestinal
40 disorders (8.3% rhu-pGSN; 0% placebo), and nervous system disorders (12.5% rhu-pGSN; 12.5%
41 placebo). No AEs by preferred term were reported by more than 1 subject in either arm. Three
42 subjects (12.5%) experienced an AE assessed as related to study drug. No serious AEs occurred,
43 and no AEs led to study discontinuation, dose interruption/reduction, or death. There were no
44 apparent between-treatment differences in laboratory abnormalities, vital signs, or
45 electrocardiogram findings.

46 **Conclusions** Overall, in this study, IV rhu-pGSN (up to 24 mg/kg daily) appeared safe and well
47 tolerated compared to placebo. The median half-life of rhu-pGSN exceeded 14 h across all dosing
48 regimens, supporting once daily IV dosing in healthy subjects.

49 **Trial registration** This study was registered with ClinicalTrials.gov on 2023-03-29 under the
50 registration identifier NCT05789745.

51 **Background**

52 Plasma gelsolin (pGSN) is a non-immunosuppressive, anti-inflammatory protein produced
53 and secreted by virtually every cell type, and it circulates at high levels in the blood of healthy
54 individuals (100-300 ug/ml) (1). The natural protein, and its recombinant counterpart (rhu-pGSN),
55 are comprised of 755 amino acids and are non-glycosylated. Extensive experimental work has
56 shown that pGSN exerts broad anti-inflammatory and host-protective effects, including
57 scavenging extracellular actin, binding inflammatory mediators, enhancing pathogen clearance,
58 inhibiting activation of the NLRP3 inflammasome, and promoting the transition of macrophages
59 from a proinflammatory (M1) to an anti-inflammatory (M2) phenotype (2–8).

60 Circulating pGSN levels decline substantially in a wide range of acute and chronic diseases,
61 including trauma, infections, neurologic disorders and many others (9–13). It is noteworthy that
62 the lower the levels of plasma gelsolin, the less favorable the prognosis of acute illness becomes
63 (9). This association has been observed in several acute lung injury (ALI) conditions, such as
64 community-acquired pneumonia (CAP) (9), COVID-19 (14–16), ALI after cardiac bypass (17) or
65 allogeneic stem cell transplantation (18) and ventilator weaning in critically ill patients (19).

66 The functional importance of pGSN in modulating inflammation is further supported by
67 animal studies in which pGSN depletion exacerbates diseases, while rhu-pGSN administration
68 improves outcomes across diverse models whose main common denominator is dysregulated
69 inflammation. These include sepsis (20), arthritis (21), decompression sickness (7,22) and CO-
70 induced neurological injury (23). Notably, rhu-pGSN has also shown consistent benefits in

71 preclinical models of lung injury, including bacterial pneumonia (3,24), influenza (25) and
72 hyperoxia (26).

73 Together, these findings provide two complementary lines of evidence supporting the
74 therapeutic potential of rhu-pGSN administration in ARDS/ALI: (1) clinical observations linking
75 low endogenous pGSN levels to worse outcomes, and (2) preclinical studies demonstrating
76 improved outcome with pGSN administration in animal models of inflammatory lung injuries.

77 We conducted a phase-1 clinical study to evaluate the safety, tolerability and
78 pharmacokinetics of rhu-pGSN in healthy volunteers, providing the foundation for the now
79 ongoing phase-2 trial in moderate-to-severe ARDS (NCT05947955).

80 **Methods**

81 **Objective**

82 The primary objective of this study (NCT05789745) was to evaluate the safety and
83 tolerability of 4 sequentially ascending doses of rhu-pGSN at 6 mg/kg, 12 mg/kg, 18 mg/kg and
84 24 mg/kg[a] of actual body weight administered by intravenous (IV) infusion for 5 doses at 0, 12,
85 36, 60, and 84 hours to healthy subjects. Secondary objectives include characterization of the
86 pharmacokinetic profile of rhu-pGSN, as well as investigation of the development of anti-pGSN
87 antibodies following administration of 5 doses of rhu-pGSN to healthy subjects.

88 **Study Materials**

89 Rhu-pGSN (BioAegis Therapeutics, North Brunswick, NJ) was produced in *Escherichia coli*
90 and subsequently purified and lyophilized under good manufacturing practice (GMP) procedures.

91 The study site received 10-ml glass vials containing lyophilized powder, which were reconstituted
92 with 4.9 ml of sterile water to yield approximately 5.3 ml of solution at a final concentration of 40
93 mg/ml[a] rhu-pGSN in a proprietary stabilizing buffer.

94 **Study Design and Participants**

95 This phase I, randomized, double-blind, placebo-controlled, dose escalation, parallel design study
96 was conducted from February 14, 2023 through May 22, 2023, by Nucleus Network at Saint Paul,
97 Minnesota. A total of 32 healthy volunteers aged 18 to 55 years, with body weight ≤ 100 kg, and
98 a body mass index < 30 kg/m^2, were enrolled. The clinical study protocol and any other
99 appropriate study-related documents were reviewed and approved by the Institutional Review
100 Board (IRB). Written informed consent was obtained from all participants. Participants were
101 excluded if they were pregnant or lactating women; had acute illness during the month prior to
102 screening; required any medications during the 5 inpatient days other than acetaminophen; were
103 hospitalized during the year prior to screening; had a history of cancer or treatment with
104 chemotherapy or radiation therapy; had a history of transplantation; had a history of diabetes
105 mellitus, cardiovascular disease, cerebrovascular disease, pulmonary disease, liver or kidney
106 disease, psychiatric condition, or active or chronic infection; received blood products during the
107 year prior to screening; underwent chronic mechanical ventilation or dialysis; had any clinically
108 significant abnormalities in clinical chemistry, hematology, urinalysis results, vital signs, EKG, or
109 physical examination findings as judged by the Investigator; or positive results for recreational
110 drugs during screening. Full inclusion and exclusion criteria are listed in the Supplementary
111 Materials.

112 Thirty-two healthy volunteers were assigned to 4 sequentially ascending dose cohorts (6,
113 12, 18, 24 mg/kg of body weight) to receive five IV infusions of rhu-pGSN or saline placebo (Fig.
114 1). Each cohort includes 8 subjects randomized 3:1 with rhu-pGSN or placebo (6 rhu-pGSN
115 subjects: 2 placebo subjects). Doses were administered at 0 hours (Day 1), 12 hours (Day 1), 36
116 hours (Day 2), 60 hours (Day 3), and 84 hours (Day 4). Subjects stayed at the study site until after
117 the last blood sample was taken at 108 hours (Day 5). Subjects returned for follow-up 7 days after
118 the initiation of therapy (on Day 8) and on Day 28 for the End-of-Study (EOS) visit. After each
119 cohort completed the Day 8 visit, a review of the safety results was conducted before the
120 initiation of the next higher dose cohort. The entire study was 28 ± 3 days in duration.

121 **Procedures**

122 Participants were admitted to the clinical site 1 day before study drug administration and
123 remained there until 24 hours after the last dosing (on Day 5). Plasma samples for
124 pharmacokinetic analysis were collected within 15 minutes before, and at 15 minutes and 1, 2, 4,
125 8 and 12 hours after Dose #1, #2 and #5, respectively; additional plasma samples were collected
126 at 24 hours after Dose #2 and #5. A single plasma sample for pharmacokinetic analysis was also
127 collected anytime on Days 8 and 28. Serum samples were collected on Day 1 before Dose #1 and
128 on Day 28 for assessing the presence of anti-rhu-pGSN antibodies. Participants were monitored
129 for adverse events (AEs), clinical laboratory measurements, vital signs, and electrocardiogram
130 (EKG) measurements.

131 **Outcomes**

132 AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version
133 25.1. Plasma pGSN concentrations were measured by enzyme-linked immunosorbent assay
134 (ELISA) as previously described (27). Since the assay measured endogenous pGSN levels as well
135 as exogenous rhu-pGSN, pharmacokinetic parameters were calculated for values above baseline
136 by subtracting pre-dose pGSN level from each observed concentration. Baseline-adjusted
137 concentrations that are <0 were set to 0. The pharmacokinetic parameters were calculated by
138 Phoenix WinNonlin version 6.3 or higher (Certara, Princeton, New Jersey), which include but not
139 limited to maximum concentration (C_{max}), time to maximum concentration (T_{max}), terminal half-
140 life ($t_{1/2}$), area under the concentration-time curve (AUC) from time 0 to 8h (AUC_{0-8}), AUC from 0
141 to 12h (AUC_{0-12}), AUC from 0 to 24h (AUC_{0-24}), and AUC from 0 to infinity (AUC_{0-inf}). For the
142 assessment of anti-rhu-pGSN antibody in serum samples, a Meso Scale Diagnosistics (MSD) based
143 electrochemiluminescent immunoassay was used. It utilizes the bivalent binding capability of
144 anti-pGSN antibodies to form a bridging complex with biotinylated Protein G and ruthenylated
145 pGSN to generate RLU (relative light units) for the measurement of anti-pGSN antibodies in matrix.
146 Samples were tested in a three-tier approach. All samples were initially evaluated in a screening
147 assay (Tier I) to detect the presence of antibody, samples with positive signals (signals above the
148 calculated screening assay cut point value) were further evaluated in a confirmatory assay (Tier
149 II) to determine the specificity of the reactivity. Samples confirmed positive (signals above the
150 confirmatory assay cut point value) were evaluated in a titration assay (Tier III) to semi-quantitate
151 the anti-rhu-pGSN antibody by reporting a titer.

152 **Statistical Analysis**

153 The sample size was 32 subjects in total: 6 subjects received rhu-pGSN and 2 subjects
154 received placebo in each of the 4 dosing cohorts. Data from all subjects who received placebo
155 were combined into a single placebo group.

156 Safety was assessed in all subjects who were randomized and received at least part of one
157 dose of study treatment (Safety Population). Pharmacokinetics were assessed in all subjects in
158 the safety population who had at least 1 quantifiable study drug concentration post-dose (PK
159 Population). The Per Protocol (PP) Population was to exclude all subjects in the Safety Population
160 who had missed or mistimed doses, received the wrong dose, and/or randomly discontinued the
161 study before the primary Day 8 visit.

162 Continuous variables were summarized using descriptive statistics, including the number
163 of subjects (N) with non-missing values, mean, standard deviation (SD), median, minimum, and
164 maximum. For PK data, geometric mean, coefficient of variation (CV%), and geometric coefficient
165 of variation (geo CV%) values were also presented. In summary tables of categorical variables,
166 frequency counts and percentages of subjects within each category were presented.

167 All statistical analysis was performed using SAS version 9.4 (SAS Institute, Cary, North
168 Carolina).

169 [a] Subsequent to conducting this study, it was determined that the extinction coefficient used
170 historically to determine protein concentration for plasma gelsolin underreported the actual
171 protein levels. Theoretical and experimental determination of the extinction coefficient confirms
172 that these values are underreported by 11%. Thus, this study was performed at doses that were

173 11% higher than reported below. The values reported here used the previous extinction
174 coefficient and are not adjusted.

175 **Results**

176 **Participants**

177 A total of 32 subjects were screened and all were randomized with rhu-pGSN (N=24; 6 in
178 each of the 4 cohorts) or placebo (N=8). One subject discontinued the study due to withdrawal
179 of consent (subject moved to another state). All other participants completed the study (Fig. 2).

180 The mean (SD) age of the 32 subjects was 36.2 (11.0) years (range: 20.0 to 55.0 years;
181 Table 1). Twenty subjects (62.5%) were male, and twelve subjects (37.5%) were female. Most
182 subjects were White (75.0%); the remainder of the subjects were Asian or African American
183 (12.5% each). The mean BMI (SD) was 24.7 (2.9).

184 One subject in Cohort 1 (6 mg/kg) was transgender (male to female). The gender used for
185 study purposes was the same as that assigned on the subject' s birth certificate (male). This
186 ensured consistency in controlling for biological differences in physical characteristics between
187 the sexes, such as when measuring pharmacokinetic parameters.

188 Demographics and baseline characteristics were generally well balanced across rhu-pGSN
189 and placebo groups with the exception of gender; the ratio of male to female subjects in the
190 placebo group (7:1) was higher than the ratio of male to female subjects across the rhu-pGSN
191 groups (range: 4:2 to 3:3). Placebo recipients were younger than rhu-pGSN recipients overall.

192 **Safety**

193 10 of 24 subjects (41.7%) who received rhu-pGSN reported a total of 13 AEs, 11 of which
194 were treatment-emergent AEs (TEAEs). 1 of 8 subject (12.5%) who received placebo reported 1
195 AE, which was also a TEAE (Table 2). All AEs were mild or moderate. The overall proportion of
196 subjects with AEs was higher in the 18 and 24 mg/kg dose groups (50.0%) and lower in the 6 and
197 12 mg/kg dose groups (33.3%). Events in any specific system organ classes occurred in ≤3 subjects
198 in either arm (Table 3). AEs in system organ classes that were reported by 2 or more subjects in
199 either arm were skin and subcutaneous tissue disorders (12.5% rhu-pGSN; 0% placebo),
200 gastrointestinal disorders (8.3% rhu-pGSN; 0% placebo), and nervous system disorders (12.5%
201 rhu-pGSN; 12.5% placebo). No AEs by preferred term were reported by more than 1 subject in
202 either arm. Three subjects (12.5%) experienced an AE assessed as related (including definitely
203 related, probably related and possibly related) to study drug, which were constipation, fatigue,
204 and epigastric discomfort (Table 2, Supplementary Table 1). No AEs were serious and none led to
205 study discontinuation, interruption or reduction of study drug, or death. There were no clear
206 differences between the treatments over time in mean or median laboratory variables. Selected
207 summary statistics of key hematology parameters of special interest by dose group are
208 summarized in Supplementary Table 2. There were no between-treatment differences in vital
209 signs, or EKG findings, either.

210 **Pharmacokinetics**

211 **Plasma Concentrations of rhu-pGSN**

212 Among the 32 subjects who were randomized with rhu-pGSN (N=24) or placebo (N=8),
213 one subject in the 18 mg/kg group had a major protocol deviation that led to exclusion of her

214 data from the Per Protocol (PP) population. Summary statistics of pGSN plasma concentration
215 and the PK parameters are presented only for subjects who were part of both the PK and PP
216 populations.

217 The mean baseline pGSN plasma concentrations (pre-treatment on Day 1, representing
218 endogenous pGSN) for the 6, 12, 18, and 24 mg/kg cohorts were: 64.8, 63.6, 59.6, and 72.5
219 µg/mL, respectively. The mean pGSN plasma concentration for the placebo cohort at baseline
220 was 70.0 µg/mL (Supplementary Table 3). For each individual, concentrations above the baseline
221 endogenous pGSN level were calculated by subtracting the pre-dose pGSN level from each
222 subsequent observed concentration. Baseline-adjusted concentrations that were < 0 were set to
223 zero. Mean baseline-adjusted plasma rhu-pGSN concentrations were illustrated by dose group in
224 Fig. 3A-C. The mean maximum plasma rhu-pGSN concentrations were observed within 15
225 minutes after completion of treatment with the exception of Cohort 3 (18 mg/kg) which reached
226 mean maximum plasma rhu-pGSN concentrations after Doses 1 and 2 at 1 hour after completion
227 of treatment. Mean maximum plasma rhu-pGSN concentrations declined over time across
228 cohorts, except for Cohort 3 following Dose 1 and 2, in which the 4-hour post-dose concentrations
229 exceeded those observed at 2 hours. For all other cohorts and dose groups, plasma
230 concentrations decreased gradually at each time point over the 12- or 24-hours post-treatment.
231 The mean 24-hour post-dose rhu-pGSN plasma concentrations following Dose 2 and Dose 5 are
232 summarized in Table 4. An overall dose-dependent increase in 24-hour post-dose concentrations
233 was observed, except between the 18 mg/kg and 24 mg/kg cohorts after Dose 2, which may be
234 due to high variability in the 18 mg/kg cohort after Dose 2 (Supplementary Table 5). Mean plasma
235 rhu-pGSN concentrations in all cohorts had returned to near-baseline levels by Day 28 (Table 4).

236 **Pharmacokinetic Parameters of rhu-pGSN**

237 Key PK parameters of baseline-adjusted rhu-pGSN were summarized in Table 5. Mean PK
238 parameters of rhu-pGSN showed higher exposure (AUC_{0-8}, AUC_{0-12}, AUC_{0-24}, and AUC_{0-inf}) with
239 increasing dose except for AUC_{0-inf} in Cohort 3 (18 mg/kg) after Dose 2 which was slightly higher
240 than the exposure observed in Cohort 4 (24 mg/kg) (13947.5 h* µg/mL and 13682.4 h* µg/mL,
241 respectively). This may be due to high variability in the 18 mg/kg cohort after Dose 2
242 (Supplementary Table 5). Mean $t_{1/2}$ (SD) varied from 9.2 (3.0) to 28.4 (8.5) hours across all doses
243 and cohorts and the median $t_{1/2}$ was 14.5 h in all dosing regimens, but sampling was limited to
244 24-h postdose measurements. The rhu-pGSN level rose well above baseline at C_{max} for each dose,
245 with the higher doses (18 mg/kg and 24 mg/kg) yielding pGSN levels more than 10 times the
246 baseline values.

247 **Immunogenicity**

248 At day 1 (predose), 4 out of 32 subjects were screened positive in the Tier I, but none of
249 them was confirmed positive for the presence of anti-pGSN antibodies in the Tier II (Table 6). On
250 Day 28, 18 subjects were screened positive for the presence of anti-pGSN antibodies in Tier I, 2
251 additional samples had replicate results which spanned the cut-off point. Among the 20 samples
252 requiring Tier II analysis, 18 were confirmed negative, 1 in the placebo group was confirmed
253 positive, 1 in the 24 mg/kg rhu-pGSN group has a non-reportable result. The two samples were
254 further tested in Tier III, but both show near-baseline signals at the lowest dilution tested (30-
255 fold). Therefore, it is reasonable to consider those two samples were antibody negative.

256 **Discussion**

257 We assessed the safety and tolerability of rhu-pGSN in a phase 1, randomized, double-
258 blind, placebo-controlled, multiple-dose escalation study. Prior to this study, IV administration of
259 rhu-pGSN had been evaluated by BioAegis Therapeutics in two clinical trials in hospitalized
260 patients: one in patients with mild community-acquired pneumonia (CAP) and another in
261 patients with moderate to severe SARS-CoV-2(COVID-19) (27,28). In the CAP trial, 33 subjects
262 admitted to hospital with mild CAP received 1 to 3 doses of 6 -24 mg/kg of rhu-pGSN or placebo
263 over 3 days. All tested doses of rhu-pGSN were generally well tolerated in this study, with no
264 drug-related AEs in the rhu-pGSN arms. Two subjects died during the study: one received a single
265 dose of the lowest dose of rhu-pGSN, the other received placebo (27). The COVID-19 trial enrolled
266 61 patients with World Health Organization (WHO) severity score of 4-6 to receive adjunctive
267 rhu-pGSN or placebo on top of standard-of-care. Subjects in the rhu-pGSN arm received three
268 doses of 12 mg/kg rhu-pGSN at entry, 12 hours and 36 hours. Rhu-pGSN was well tolerated, with
269 numerically fewer subjects experiencing SAEs in the rhu-pGSN group (5 subjects; 16.7%) than in
270 the placebo group (8 subjects; 25.8%) (28).

271 The current study significantly expanded the safety profile characterization of pGSN
272 beyond that achieved in previous studies which were limited to up to three doses. In the current
273 study, the safety, tolerability, and pharmacokinetics of five doses of rhu-pGSN, ranging from 6
274 mg/kg to 24 mg/kg, were evaluated in healthy volunteers. Doses of rhu-pGSN or placebo were IV
275 administered at 0 h, 12 h, 36 h, 60 h and 84 h. Infusion with increasing doses of rhu-pGSN yielded
276 a sustained dose-dependent increase in pGSN levels in the circulation. Repeated dosing did not
277 lead to significant drug accumulation. In the higher rhu-pGSN dosing cohorts (18 and 24 mg/kg),
278 peak pGSN concentrations exceeded 10 times the physiological level, without any SAEs or AEs

279 that led to study discontinuation or interruption. The half-life of rhu-pGSN in different dosing
280 regimens varied between 9.2 h and 28.4 h, with the median half-life of rhu-pGSN exceeding 14 h
281 across all dosing regimens, supporting once daily IV dosing in the healthy subjects studied in this
282 trial. A total of 13 AEs were reported by 10 of 24 subjects (41.7%) who received rhu-pGSN,
283 whereas 1 AE was reported by 1 of 8 subject (12.5%) who received placebo. All AEs were mild or
284 moderate. No apparent association was observed between the rhu-pGSN dose and the frequency
285 or types of AEs reported.

286 **Conclusions**

287 Overall, IV administration of five doses of rhu-pGSN up to 24 mg/kg over 5 days was safe
288 and well tolerated in this small trial in healthy volunteers. In the higher dosing cohorts, even with
289 pGSN levels maintained well above physiological concentration over the 5 days, neither SAEs nor
290 AEs that led to study discontinuation/interruption were observed. The median half-life of rhu-
291 pGSN exceeded 14 h across all dosing regimens, supporting once daily IV dosing in healthy
292 subjects. A phase 2 proof-of-concept trial evaluating the efficacy and safety of rhu-pGSN in
293 addition to standard of care in subject with moderate-to severe ARDS due to pneumonia or other
294 infections is currently ongoing.

295 **List of abbreviations**

AE	adverse events
ALI	acute lung injury
ARDS	acute respiratory distress syndrome

BMI	body mass index
CAP	community-acquired pneumonia
EKG	electrocardiogram
ELISA	enzyme-linked immunosorbent assay
EOS	End of Study
IRB	Institutional Review Board
IV	intravenous
MedDRA	Medical Dictionary for Regulatory Activities
PK	pharmacokinetic(s)
PP	Per Protocol
rhu-pGSN	recombinant human plasma gelsolin
SAE	serious adverse event
TEAE	treatment-emergent adverse event

296

297 **Declarations**

298 **Human ethics approval and consent to participate declaration**

299 The study was designed and conducted in accordance with the Declaration of Helsinki and was
300 approved by Advarra' s Institutional Review Board (IRB# Pro00069641) before the start of the
301 trial. Written informed consent was obtained from all participants.

302 **Consent for publication**

303 Not applicable

304 **Availability of data and materials**

305 The datasets used and/or analyzed during the current study are available from the corresponding
306 author on reasonable request.

307 **Competing interests**

308 Y.L., S.L.L., E.K., J.P. are employees of BioAegis Therapeutics, which is developing recombinant
309 human plasma gelsolin (rhu-pGSN) for clinical use. L. K. is a paid consultant to BioAegis and owns
310 stock in the company. S. L. L. is the Chief Executive Officer and M. J. D. was the Chief Medical
311 Officer at the time of the study, both of whom own stock in the company.

312 **Funding**

313 BioAegis Therapeutics funded the study. The trial was designed and managed by BioAegis
314 Therapeutics in collaboration with a CRO.

315 **Authors' contribution**

316 YL analyzed and interpreted the data, and wrote the first draft of the manuscript. SL and MJD
317 contributed to the design, execution and data analysis of the clinical trial. EK and JP performed
318 the plasma gelsolin ELISA. LK contributed to manuscript writing. All coauthors reviewed and
319 approved the final version of the manuscript.

320 **Acknowledgements**

321 Recombinant human plasma gelsolin was provided by BioAegis Therapeutics.

322 We thank Nucleus Network for invaluable help conducting the trial and Jennifer Stanley for CSR
323 preparation.

324 We also thank all the healthy volunteers who participated in the trial, as well as the principal
325 investigator at the study site: Trisha Shamp (Saint Paul, Minnesota).

326 **References**

327 1. Smith DB, Janmey PA, Herbert TJ, Lind SE. Quantitative measurement of plasma gelsolin and
328 its incorporation into fibrin clots. J Lab Clin Med. 1987 Aug;110(2):189–95.

329 2. Ordija CM, Chiou TTY, Yang Z, Deloid GM, de Oliveira Valdo M, Wang Z, et al. Free actin
330 impairs macrophage bacterial defenses via scavenger receptor MARCO interaction with
331 reversal by plasma gelsolin. American Journal of Physiology–Lung Cellular and Molecular
332 Physiology. 2017;312(6):L1018–28.

333 3. Yang Z, Chiou TTY, Stossel TP, Kobzik L. Plasma gelsolin improves lung host defense against
334 pneumonia by enhancing macrophage NOS3 function. American Journal of Physiology–Lung
335 Cellular and Molecular Physiology. 2015;309(1):L11–6.

336 4. Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to
337 lysophosphatidic acid and platelet-activating factor by plasma gelsolin. American Journal of
338 Physiology-Cell Physiology. 2007;292(4):C1323–30.

339 5. Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Chaby R, et al. Inactivation of
340 endotoxin by human plasma gelsolin. Biochemistry. 2005;44(28):9590–7.

341 6. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding
342 protein in clearing actin from the circulation. The Journal of Clinical Investigation.
343 1986;78(3):736–42.

344 7. Bhopale VM, Ruhela D, Brett KD, Nugent NZ, Fraser NK, Levinson SL, et al. Plasma gelsolin
345 modulates the production and fate of IL-1β-containing microparticles following high-
346 pressure exposure and decompression. Journal of Applied Physiology. 2021;130(5):1604–13.

347 8. Sharma RK, Goswami B, Das Mandal S, Guha A, Willard B, Ray PS. Quorum sensing by
348 gelsolin regulates programmed cell death 4 expression and a density-dependent phenotype
349 in macrophages. The Journal of Immunology. 2021;207(5):1250–64.

350 9. Self WH, Wunderink RG, DiNubile MJ, Stossel TP, Levinson SL, Williams DJ, et al. Low
351 admission plasma gelsolin concentrations identify community-acquired pneumonia patients
352 at high risk for severe outcomes. Clinical Infectious Diseases. 2019;69(7):1218–25.

10. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. American Journal of Respiratory and Critical Care Medicine. 1999;160(5):1673–81.

11. Güntert A, Campbell J, Saleem M, O' Brien DP, Thompson AJ, Byers HL, et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer' s disease. Journal of Alzheimer' s Disease. 2010;21(2):585–96.

12. Kulakowska A, Drozdowski W, Sadzynski A, Bucki R, Janmey PA. Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders. European Journal of Neurology. 2008;15(6):584–8.

13. Osborn TM, Verdrengh M, Stossel TP, Tarkowski A, Bokarewa M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Research & Therapy. 2008;10(5):R117.

14. Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, Jesus AAA de, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight [Internet]. 2021 Jan 11 [cited 2026 Jan 23];6(1). Available from: https://insight.jci.org/articles/view/144455

15. Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Systems. 2020;11(1):11–24.

16. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al. Large-scale multi-omic analysis of COVID-19 severity. Cell Systems. 2021;12(1):23–40.

17. Shi S, Chen C, Zhao D, Liu X, Cheng B, Wu S, et al. The role of plasma gelsolin in cardiopulmonary bypass–induced acute lung injury in infants and young children: a pilot study. BMC Anesthesiology. 2014;14(1):67.

18. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002;100(13):4367–71.

19. Holm FS, Sivapalan P, Seersholm N, Itenov TS, Christensen PH, Jensen JUS. Acute lung injury in critically ill patients: actin-scavenger gelsolin signals prolonged respiratory failure. Shock. 2019;52(3):370–7.

20. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Critical Care Medicine. 2007;35(3):849–55.

21. Lee J, Sasaki F, Koike E, Cho M, Lee Y, Dho SH, et al. Gelsolin alleviates rheumatoid arthritis by negatively regulating NLRP3 inflammasome activation. Cell Death & Differentiation. 2024;31(12):1679–94.

22. Bhat AR, Arya AK, Bhopale VM, Imtiyaz Z, Thom SR. Recombinant human plasma gelsolin suppresses persistent neuroinflammation and restores hippocampal neurogenesis in murine model of decompression sickness. Journal of Neurophysiology. 2024;132(6):1877–86.

23. Arya AK, Sethuraman K, Waddell J, Cha YS, Liang Y, Bhopale VM, et al. Inflammatory responses to acute carbon monoxide poisoning and the role of plasma gelsolin. Sci Adv. 2025 Feb 7;11(6):eado9751.

24. DiNubile MJ, Levinson SL, Stossel TP, Lawrenz MB, Warawa JM. Recombinant human plasma gelsolin improves survival and attenuates lung injury in a murine model of multidrug-resistant Pseudomonas aeruginosa pneumonia. Open Forum Infectious Diseases. 2020;7(8):ofaa236.

25. Yang Z, Bedugnis A, Levinson S, DiNubile M, Stossel T, Lu Q, et al. Delayed administration of recombinant plasma gelsolin improves survival in a murine model of penicillin-susceptible and penicillin-resistant pneumococcal pneumonia. The Journal of Infectious Diseases. 2019;220(9):1498–502.

26. Cui TX, Brady AE, Zhang YJ, Fulton CT, Popova AP. Gelsolin attenuates neonatal hyperoxia-induced inflammatory responses to rhinovirus infection and preserves alveolarization. Frontiers in Immunology. 2022;13:792716.

27. Tannous A, Levinson SL, Bolognese J, Opal SM, DiNubile MJ. Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy. 2020 Sept 21;64(10):10.1128/aac.00579-20.

28. DiNubile MJ, Parra S, Salomó AC, Levinson SL. Adjunctive Recombinant Human Plasma Gelsolin for Severe Coronavirus Disease 2019 Pneumonia. Open Forum Infectious Diseases. 2022 Aug 2;9(8):ofac357.

420 **Tables**

421 **Table 1. Subject demographics**

Parameter	rhu-pGSN 6 mg/kg N=6	rhu-pGSN 12 mg/kg N=6	rhu-pGSN 18 mg/kg N=6	rhu-pGSN 24 mg/kg N=6	Placebo N=8	Overall N=32
Age (yr)						
Mean (SD)	35.3 (10.2)	42.2 (4.1)	37.7 (14.7)	37.0 (15.4)	30.5 (7.4)	36.2 (11.0)
Median	34.0	41.5	36.0	37.5	28.5	36.5
Range	25-54	38-48	20-55	20-52	21-43	20-55
Gender, n (%)						
Male	4 (66.7)	3 (50.0)	3 (50.0)	3 (50.0)	7 (87.5)	20 (62.5)
Female	2 (33.3)	3 (50.0)	3 (50.0)	3 (50.0)	1 (12.5)	12 (37.5)
Ethnicity, n (%)						
Not Hispanic or Latino	4 (66.7)	5 (83.3)	6 (100)	5 (83.3)	7 (87.5)	27 (84.4)
Hispanic or Latino	2 (33.3)	1 (16.7)	0	1 (16.7)	1 (12.5)	5 (15.6)
Race, n (%)						
Asian	0	0	1 (16.7)	3 (50.0)	0	4 (12.5)
Black or African American	1 (16.7)	1 (16.7)	0	0	2 (25.0)	4 (12.5)
White	5 (83.3)	5 (83.3)	5 (83.3)	3 (50.0)	6 (75.0)	24 (75.0)
BMI (kg/m^2)						
Mean (SD)	24.6 (2.9)	24.8 (3.5)	25.3 (3.7)	25.4 (2.9)	23.9 (2.0)	24.7 (2.9)
Median	24.5	24.7	26.6	26.0	23.9	24.8
Range	19.5-27.9	20.8-28.8	19.0-29.7	21.9-29.1	21.2-26.4	19.0-29.7

422

423

424

425

426 **Table 2. Overview of adverse events in the Safety Population**

Parameter	rhu-pGSN 6 mg/kg N=6	rhu-pGSN 12 mg/kg N=6	rhu-pGSN 18 mg/kg N=6	rhu-pGSN 24 mg/kg N=6	rhu-pGSN Combined N=24	Placebo N=8
No. of AEs	2	3	5	3	13	1
No. of Treatment-emergent AEs (TEAEs)	1	3	5	2	11	1
No. (%) of subjects with at least 1:						
AE	2 (33.3)	2[a] (33.3)	3[b] (50.0)	3 (50.0)	10 (41.7)	1 (12.5)
Serious AE	0	0	0	0	0	0
AE leading to study discontinuation	0	0	0	0	0	0
AE leading to study interruption	0	0	0	0	0	0
AE leading to death	0	0	0	0	0	0
TEAE	1 (16.7)	2 (33.3)	3 (50.0)	2 (33.3)	8 (33.3)	1 (12.5)
No. (%) of subjects with AEs by NCI-CTCAE grade						
1 - Mild	1 (16.7)	2[a] (33.3)	3[b] (50.0)	2 (33.3)	8 (33.3)	1 (12.5)
2 - Moderate	1 (16.7)	1[a] (16.7)	0	1 (16.7)	3 (12.5)	0
3 - Severe	0	0	0	0	0	0
4 - Life-threatening	0	0	0	0	0	0
5 - Fatal	0	0	0	0	0	0
No. (%) of subjects with AEs by relationship to study drug						
Definitely unrelated	2 (33.3)	2[a] (33.3)	2[b] (33.3)	2 (33.3)	8 (33.3)	0
Probably unrelated	0	0	1[b] (16.7)	0	1 (4.2)	1 (12.5)
Possibly related	0	0	2[b] (33.3)	1 (16.7)	3 (12.5)	0
Probably related	0	0	0	0	0	0
Definitely related	0	0	0	0	0	0
No. (%) of subjects with AEs by relationship to study procedure						
Definitely unrelated	1 (16.7)	2[a] (33.3)	3[b] (50.0)	3 (50.0)	9 (37.5)	1 (12.5)
Probably unrelated	0	0	1[b] (16.7)	0	1 (4.2)	0
Possibly related	0	0	0	0	0	0
Probably related	0	0	0	0	0	0
Definitely related	1 (16.7)	1[a] (16.7)	0	0	2 (8.3)	0

427 [a]One subject experienced two AEs: one mild and one moderate. Both AEs were deemed definitely
428 unrelated to study drug. One AE was deemed definitely unrelated to study procedure, the other
429 definitely related.

430 [b]One subject experienced three AEs, all of which were mild. One AE was deemed definitely unrelated to
431 study drug, one probably unrelated, and one possibly related. Three AEs were deemed definitely
432 unrelated to study procedure, and one probably unrelated.
433
434 **Table 3. Summary of adverse events by System Organ Class and Preferred Term in the Safety**
435 **Population**

	rhu-pGSN					
System Organ Class Preferred Term	**6 mg/kg N=6 No. (%)**	**12 mg/kg N=6 No. (%)**	**18 mg/kg N=6 No. (%)**	**24 mg/kg N=6 No. (%)**	**Combined N=24 No. (%)**	**Placebo N=8 No. (%)**
Skin and subcutaneous tissue disorders	0	1 (16.7)	1 (16.7)	1 (16.7)	3 (12.5)	0
Dermatitis	0	0	0	1 (16.7)	1 (4.2)	0
Ecchymosis	0	1	0	0	1 (4.2)	0
Rash	0	0	1 (16.7)	0	1 (4.2)	0
Gastrointestinal disorders	0	0	1 (16.7)	1 (16.7)	2 (8.3)	0
Constipation	0	0	1 (16.7)	0	1 (4.2)	0
Epigastric discomfort	0	0	0	1 (16.7)	1 (4.2)	0
Nervous system disorders	1 (16.7)	1 (16.7)	0	1 (16.7)	3 (12.5)	1 (12.5)
Dizziness	1 (16.7)	0	0	0	1 (4.2)	0
Headache	0	0	0	1 (16.7)	1 (4.2)	1 (12.5)
Muscle contractions involuntary	0	1	0	0	1 (4.2)	0
General disorders and administration site conditions	0	0	1 (16.7)	0	1 (4.2)	0
Fatigue	0	0	1 (16.7)	0	1 (4.2)	0
Infections and infestations	0	1 (16.7)	0	0	1 (4.2)	0
Urinary tract infection	0	1 (16.7)	0	0	1 (4.2)	0
Injury, poisoning and procedural complications	1 (16.7)	0	0	0	1 (4.2)	0
Muscle strain	1 (16.7)	0	0	0	1 (4.2)	0
Musculoskeletal and connective tissue disorders	0	0	1 (16.7)	0	1 (4.2)	0
Arthralgia	0	0	1 (16.7)	0	1 (4.2)	0

436

437 **Table 4. Mean baseline-adjusted plasma concentrations of rhu-pGSN at 24 hours post-dose,**
438 **and on Day 8 and 28 in subjects who were part of both the PK and PP populations**

	rhu-pGSN				
Time Points	**6 mg/kg N=6**	**12 mg/kg N=6**	**18 mg/kg N=5[a]**	**24 mg/kg N=6**	**Placebo N=8**
24-hour post Dose 2	72.3 (19.3)	142.7 (24.5)	218.0 (74.6)	204.5 (50.1)	1.6 (4.6)
24-hour post Dose 5	125.9 (58.0)	156.9 (19.4)	228.0 (29.5)	269.4 (26.2)	2.7 (5.4)
Day 8	36.0 (23.0)	40.5 (16.2)	46.4 (23.6)	46.9 (24.2)	6.1 (6.7)
Day 28	19.7 (16.3)	8.4 (9.5)	18.5 (7.7)	9.3 (10.7)	4.2 (6.1)

439 [a] One subject in the 18 mg/kg group had a major protocol deviation that led to exclusion of her data from the Per
440 Protocol (PP) population.
441

442

443 **Table 5. Summary of mean pharmacokinetics parameters in subjects who were part of both**
444 **the PK and PP populations**

Geometric Mean Parameters (SD)	rhu-pGSN 6 mg/kg N=6	12 mg/kg N=6	18 mg/kg N=5[a]	24 mg/kg N=6
		Dose 1		
C_{max} (µg/mL)[b]	148.4 (26.8)	347.5 (41.2)	442.5 (50.2)	663.6 (110.8)
AUC_{0-8} (h*µg/mL)[b]	912.4 (201.9)	2010.0 (261.8)	2659.9 (474.3)	2695.6 (475.1)
AUC_{0-12} (h*µg/mL)[b]	1245.5 (257.9)	2737.5 (379.1)	3547.0 (657.3)	4832.3 (646.6)
$t_{1/2}$ (h)	14.0 (5.4)	13.1 (2.6)	9.2 (3.0)	10.7 (5.2)
		Dose 2		
C_{max} (µg/mL)[b]	225.2 (27.0)	506.9 (78.5)	691.5 (110.5)	855.7 (200.6)
AUC_{0-8} (h*µg/mL)[b]	1422.9 (179.6)	3089.9 (388.7)	4389.6 (851.8)	5132.3 (1013.6)
AUC_{0-12} (h*µg/mL)[b]	1953.6 (234.5)	4194.6 (448.6)	6022.1 (1376.2)	6859.8 (1318.6)
AUC_{0-24} (h*µg/mL)[b]	3066.2 (256.8)	6448.5 (599.5)	9374.2 (2456.0)	10258.2 (2035.6)
AUC_{0-inf} (h*µg/mL)[b]	4857.8 (933.3)	9394.8 (1641.5)	13947.5 (4245.5)	13682.4 (3094.3)
$t_{1/2}$ (h)	16.7 (6.1)	14.5 (3.4)	15.1 (4.5)	12.0 (1.5)
		Dose 5		
C_{max} (µg/mL)[b]	218.9 (37.7)	501.6 (60.4)	703.8 (140.7)	970.9 (87.9)
AUC_{0-8} (h*µg/mL)[b]	1371.8 (252.5)	3033.3 (329.1)	4257.9 (561.1)	5750.0 (539.1)
AUC_{0-12} (h*µg/mL)[b]	1958.7 (463.3)	4131.6 (579.1)	5770.0 (632.3)	7824.6 (816.2)
AUC_{0-24} (h*µg/mL)[b]	3486.5 (1035.2)	6599.1 (1334.2)	9139.1 (793.1)	12135.3 (1172.4)
AUC_{0-inf} (h*µg/mL)[b]	6634.8 (2055.4)	12006.2 (7502.8)	14909.2 (1294.6)	17779.1 (1810.9)
$t_{1/2}$ (h)	28.4 (8.5)	22.0 (11.3)	17.6 (1.9)	14.5 (2.2)

445 [a] One subject in the 18 mg/kg group had a major protocol deviation that led to exclusion of her data from the Per
446 Protocol (PP) population.
447 [b] Baseline pGSN concentrations (pre-Dose 1, Day 1) were subtracted from each observed concentration of each
448 subject.
449
450
451
452

453 **Table 6 Frequencies of anti-drug antibodies at day 1 (predose) and day 28 in different cohorts**

	rhu-pGSN					
	6 mg/kg No.	12 mg/kg No.	18 mg/kg No.	24 mg/kg No.	Placebo No.	Total No.
D1						
Tested	6	6	6	6	8	32
Screened positive in Tier I	0	1	0	1	2	4
Confirmed positive in Tier II	0	0	0	0	0	0
D28						
Tested	6	6	6	6	8	32
Screened positive in Tier I	2[a]	4	5	5[b]	2	18
Confirmed positive in Tier II	0	0	0	0[c]	1	1
Considered as positive after Tier III	0	0	0	0	0	0

454 [a]One additional sample has two replicates spanning the cut-off point and therefore tested in Tier II
455 [b]One additional sample has two replicates spanning the cut-off point and therefore tested in Tier II
456 [c]One additional sample has a non-reportable Tier II result, which was further tested in Tier III
457

458 **Figures**

459 **Fig 1. Study design and dosing regimen**



460

461 **Fig 2. Patient disposition**



462

463 [a]One subject discontinued the study due to withdrawal of consent (subject moved to another state)

464 **Fig. 3 Mean baseline-adjusted plasma rhu-pGSN concentrations following dose 1 (A), dose 2**
465 **(B) and dose 5 (C) in subjects who were part of both the PK and PP populations**



466

467 **Supplemental Materials**

468 Additional file 1. Study protocol

469 Additional file 2. Inclusion and exclusion criteria, Supplementary Table 1-6

470


Cohort 1
6 mg/kg
(N = 8, 6:2)
Safety Review
Cohort 2
12 mg/kg
(N = 8, 6:2)
Safety Review
Cohort 3
18 mg/kg
(N = 8, 6:2)
Safety Review
Cohort 4
24 mg/kg
(N = 8, 6:2)
Dose#1
Dose#2
Dose#3
Dose#4
Dose#5
Safety Review
Day 1 0 h
Day 1 12 h
Day 2 36 h
Day 3 60 h
Day 4 84 h
Day 8


32 healthy volunteers enrolled
rhu-pGSN (N = 24)
• 6 mg/kg (N = 6)
• 12 mg/kg (N = 6)
• 18 mg/kg (N = 6)
• 24 mg/kg (N = 6)
Placebo (N = 8)
24 completed
7 completed[a]


A
B
C
Mean Concentration (µg/mL)
Time (Hours)
0
1
2
4
8
12
24
Cohort 1 (6 mg/kg)
Cohort 2 (12 mg/kg)
Cohort 3 (18 mg/kg)
Cohort 4 (24 mg/kg)
Placebo Cohort